Aspire Biopharma raises $2M via 8% OID debentures with 790K incentive shares

Aspire Biopharma Holdings, Inc.

Issued $2,173,913 principal of 8% OID debentures for $2,000,000; maturity sooner of 90 days or $8M financing event.
Debentures are non-convertible, bear no interest; 790,000 shares of common stock issued as incentive shares.
Proceeds to be used for debt repayment and working capital; offering exempt under Section 4(a)(2).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain investors (the “Purchasers”) valued at aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000 (effective 2026-01-26).

Action: entry
Agreement: equity purchase
Counterparty: certain investors (the “Purchasers”)
Value: aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000
Effective: 2026-01-26

Exact text from the filing

On January 26, 2026, Aspire Biopharma Holdings, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain debentures in an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-004543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.